Advancing emergency department-initiated buprenorphine.

Huntley, Kristen; Einstein, Emily; Postma, Terri; Thomas, Anita; Ling, Shari; Compton, Wilson.

Huntley K; Center for the Clinical Trials Network The National Institute on Drug Abuse Bethesda Maryland USA.
Einstein E; Office of Science Policy and Communications The National Institute on Drug Abuse Bethesda Maryland USA.
Postma T; Center for Medicare Centers for Medicare & Medicaid Services Baltimore Maryland USA.
Thomas A; Center for Clinical Standards and Quality Centers for Medicare & Medicaid Services Baltimore Maryland USA.
Ling S; Center for Clinical Standards and Quality Centers for Medicare & Medicaid Services Baltimore Maryland USA.
Compton W; Office of the Director The National Institute on Drug Abuse Bethesda Maryland USA.

J Am Coll Emerg Physicians Open ; 2(3): e12451, 2021 Jun.

文章在英语 | MEDLINE | ID: covidwho-2315508

ABSTRACT

Opioids are the main driver of drug overdose deaths in the United States, and there has been a marked increase in opioid-related overdoses during the COVID-19 public health emergency. Many emergency departments (EDs) across the country are implementing ED-initiated buprenorphine programs, and this is a method to address and prevent opioid overdoses. Resources are available to overcome barriers and take action.

Keywords

EDinitiated buprenorphine; medication for opioid use disorder; opioid use disorder; treatment engagement